MAINZ, Germany and LONDON, United Kingdom, February 8, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious ...
About BioNTech’s cell and gene therapy portfolio BioNTech has been active in the development of cell and gene therapies since 2009. Today, it is one core platform technology in BioNTech’s pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results